PPD and Southern Research Institute today announced they have formed a
collaborative agreement in pandemic and seasonal influenza vaccine
research and development to provide clients a full spectrum of influenza
vaccine development services by collaborating on client bids and
projects.
“Our agreement with Southern Research
further expands our large collection of commercial vaccine assays with
very important capabilities in the influenza vaccine field and enables
us to expand our partnerships with influenza vaccine developers in the
commercial, government and nonprofit sectors.”
As part of the agreement, Southern Research will transfer its seasonal
assays and reagents to PPD, strengthening PPD’s influenza vaccine
testing services. In return, PPD will help build Southern Research’s
preclinical influenza and clinical pandemic/highly pathogenic avian
influenza (HPAI) testing business through client referrals.
PPD is a leader in development and testing services for vaccines and
biologics and offers a large collection of commercial vaccine assays. It
provides submission support services for new and modified vaccines as
well as a wide range of other products, including blood components and
recombinant therapeutic proteins.
Southern Research is a preclinical developer and service provider of
assays for influenza vaccine sample testing and has played a key role in
the analysis and development of new and existing vaccines and antivirals
for both seasonal and highly pathogenic influenza. It is often among the
first research organizations to respond to emerging disease threats,
including highly pathogenic Avian and pandemic influenzas. Southern
Research also provides serology support for clinical trials of influenza
vaccines, including vaccines for the latest pandemic flu.